Aristotle Capital Boston LLC Decreases Position in Charles River Laboratories International, Inc. $CRL

Aristotle Capital Boston LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% during the fourth quarter, HoldingsChannel reports. The firm owned 86,214 shares of the medical research company’s stock after selling 9,134 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Charles River Laboratories International were worth $17,198,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Charles River Laboratories International by 14.5% during the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock valued at $49,626,000 after purchasing an additional 40,073 shares during the period. National Bank of Canada FI grew its stake in Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after purchasing an additional 511,901 shares in the last quarter. Gotham Asset Management LLC grew its stake in Charles River Laboratories International by 17.3% in the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock worth $49,403,000 after purchasing an additional 46,594 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $1,223,000. Finally, Nordea Investment Management AB grew its stake in Charles River Laboratories International by 43.6% in the fourth quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after purchasing an additional 16,616 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CRL. Royal Bank Of Canada started coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective on the stock. Barclays increased their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. UBS Group increased their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Mizuho set a $192.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. Finally, Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $182.97 on Thursday. The firm has a market capitalization of $8.81 billion, a price-to-earnings ratio of -48.66, a price-to-earnings-growth ratio of 2.11 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The business has a fifty day moving average of $174.31 and a 200 day moving average of $182.64. Charles River Laboratories International, Inc. has a 1 year low of $143.06 and a 1 year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.